Navigation Links
Fuisz Pharma LLC Announces Acquisition of Dysmenorrhea Treatment
Date:4/18/2011

MIAMI, April 18, 2011 /PRNewswire/ -- Fuisz Pharma announced that it has secured an exclusive license for a vaginal treatment of dysmenorrhea. The exclusive license covers existing clinical work whereby a medicated tampon was used to deliver keterolac and it includes two issued United States patents.

Joseph Fuisz, Managing Partner of Fuisz Pharma, stated, "We are pleased to announce this acquisition, having had a long standing interest in vaginal drug delivery, and in particular in the exciting patent portfolio originated by UMD prior to its acquisition by Femina Pharma."

"We look forward to seeking a marketing partner for this treatment.  The existing oral methods are not satisfactory and we believe that the market is finally taking notice of consumer acceptance of vaginal delivery."

The Fuiszes currently have a personal, majority position in Femina Pharma.  Prior to Femina's acquisition of UMD's assets, they had concluded an earlier license of UMD's technology.

Joseph Fuisz continued: "We see an exciting future for Femina's vaginal drug delivery portfolio, through the licensed technology as well as through recent allowances in the anti viral area in which vaginal delivery has interesting applications.  Vaginal delivery of anti virals is particularly exciting in view of limited absorption of many of these compounds when administered orally."

About Fuisz Pharma:

Fuisz Pharma (www.fuisz.com) is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma.


'/>"/>
SOURCE Fuisz Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. Fuisz Pharma Announces Novel Anti Abuse System for Opiates
3. FUISZ Announces Advances in Devices and Solid Dosage Form
4. Fuisz Pharma Announces Acquisition of Key Anti Opiate Abuse Patent to Complement its Anti Opiate Abuse Platform
5. Fuisz Announces Issuance of Patent for the New Generation of Glucose and Other Analyte Analyzers
6. Fuisz Pharma Releases Clinical Photos of Its Opioid Abuse Detection System
7. Fuisz Pharma LLC Develops a New Generation of Oral Solid Dosage Form Shapes That Facilitate Swallowing and Esophageal Transit
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... The global  parenteral nutrition ... by 2024, according to a new report by ... the growing malnutrition coupled with the prevalence of ... diseases are expected to boost the market over ... http://photos.prnewswire.com/prnh/20150105/723757 ) , The presence ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for treating ... becomes 5th off-the-shelf Stem cell product to be approved by a ... (also known as Thromboangiitis Obliterans) is a major unmet medical need ... Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... European Community & USA Stempeutics ...
(Date:5/30/2016)... 2016 Eye expert s ... to seek an eye examination before ...   Moorfields Eye Hospital Dubai, the first overseas ... , has identified premature babies as a special concern in ... particular vulnerability to retinopathy of prematurity (ROP). ROP is a potentially ...
Breaking Medicine Technology:
(Date:5/31/2016)... Atlanta, GA (PRWEB) , ... May 31, 2016 ... ... avoidable readmissions using a mix of advanced Artificial Intelligence (AI) and the latest ... predictive solution. The medical center is integrating predictive analytic outputs directly into the ...
(Date:5/31/2016)... MN (PRWEB) , ... May 31, 2016 , ... DDL, ... the American Association for Laboratory Accreditation (A2LA) to include ISO 594-1 and ISO 594-2 ... common means of achieving a leak-free connection between two medical devices (e.g. a syringe ...
(Date:5/31/2016)... ... May 31, 2016 , ... Spartan Bioscience ... enables unprecedented portability and convenience. , The Cube is exceptionally small—it takes up ... the Cube fits easily into any space, whether in a hospital, doctor’s office, ...
(Date:5/31/2016)... ... May 31, 2016 , ... The successful implementation of ... their laboratories as well. However, laboratories have different challenges compared to manufacturing environments. ... operations in the lab, METTLER TOLEDO has developed the Lean Lab Checklist . ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Global Wellness ... released ten predictions on the future of wellness, travel, spa and beauty in Europe. ... spa and beauty companies to leading economists and researchers - to forecast where wellness ...
Breaking Medicine News(10 mins):